Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge.
Dae Hyun LeeMerna ArmaniousJessica HuangDaniel JeongMihaela DrutaMichael G FradleyPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
To the best of our knowledge, this is the first reported case of successful re-challenge of pembrolizumab after an episode of myocarditis. In patients with mild myocarditis and no evidence of left ventricular dysfunction, re-challenge may be a viable option. However, close monitoring for the development of heart failure, cardiomyopathy, or serious arrhythmias is necessary to ensure patient safety.
Keyphrases
- patient safety
- heart failure
- left ventricular
- quality improvement
- drug induced
- advanced non small cell lung cancer
- cardiac resynchronization therapy
- healthcare
- oxidative stress
- diabetic rats
- high glucose
- acute myocardial infarction
- hypertrophic cardiomyopathy
- acute heart failure
- aortic stenosis
- acute coronary syndrome
- left atrial
- congenital heart disease
- transcatheter aortic valve replacement